Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain scanner could reveal hidden effects of childhood neurological diseases

NCT ID NCT07689682

Knowledge-focused Sponsor: Aston University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study uses a new, child-friendly brain imaging technique called OPM-MEG to understand how immune-related brain diseases (like autoimmune encephalitis and multiple sclerosis) and other brain conditions affect children aged 2 to 25. Standard scans often miss problems with memory, emotions, sleep, and social behavior. The goal is to find brain network changes that explain these issues, which could eventually help doctors predict outcomes and track brain health more accurately.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict and track long-term brain health in children with neurological diseases.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve outcomes, and the imaging technique is still being tested in young children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Sep 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 16 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. autoimmune encephalitis1, acute disseminated encephalomyelitis, multiple sclerosis. 2 * Individuals who have received a diagnosis of a non-immune mediated neurological disease (age range 2 yrs to 15 years 11 months) e.g. stroke. * Patients who can give informed consent/ assent and have a person with parental responsibility capable of giving informed consent on their behalf if aged \<16 years. Exclusion Criteria: * There is metal in the body or any other contraindication that precludes MRI scanning at IHN, or child usually requires sedation for clinical MRI scans. * Participant dissents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute disseminated encephalomyelitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute disseminated encephalomyelitis autoimmune disorder of the nervous system autoimmune encephalitis multiple sclerosis nervous system disorder stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute disseminated encephalomyelitis Autoimmune encephalitis (AE) Multiple sclerosis

Contacts and locations

Locations

  • Aston University

    Birmingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.